The FDA is reviewing 7 peptides for the compounding list. Here's what that actually means.

Under Section 503A of the Federal Food, Drug and Cosmetic (FD&C) Act, licensed compounding pharmacies and physician offices can prepare compounded drugs for individual patients without FDA approval, provided certain conditions are met.

One condition: they generally cannot compound drugs that are "essentially copies" of commercially available, FDA-approved products — except in small amounts. Another: if the drug is a bulk drug substance (a raw API, not a finished product), it must appear on the 503A Bulks List for the compounder to use it.

Getting on the 503A Bulks List means a compounding pharmacy could legally prepare that substance for a patient with a valid prescription. It does not mean:

• The substance is FDA-approved for any use
• The substance is proven safe or effective
• A compounded version meets the same quality standards as an FDA-approved drug
• Any vendor selling research peptides online is operating legally

The distinction matters. Many peptides sold online today are sold as "research chemicals" — a designation that doesn't make them legal for human use and doesn't involve compounding pharmacies at all.

The PCAC's July 2026 meeting is divided into two days, as documented in the Federal Register notice published April 16, 2026:

July 23: BPC-157, KPV, TB-500 (thymosin beta-4), MOTS-c

July 24: Emideltide (Delta Sleep-Inducing Peptide / DSIP), Semax, Epitalon

Each peptide will be evaluated individually. A favorable committee vote would recommend to the FDA that the substance could be included on the 503A Bulks List. The FDA makes the final decision — the committee's recommendation is advisory, not binding.

In 2023, the FDA reviewed a broader list of peptides and assigned many of them to "category 2" — substances that raised safety concerns based on available evidence. Several peptides on the July 2026 review list were previously in this category, including BPC-157.

Category 2 doesn't mean permanently banned. It means the FDA had concerns it wanted addressed before considering compounding access. The July 2026 review is where additional evidence and public comment will be considered. The outcome could be a recommendation for inclusion on the 503A list, a continued restriction, or a finding that more evidence is needed.

The PCAC is made up of pharmacists, physicians, patients, and scientific experts. Its role is to evaluate evidence and make non-binding recommendations to the FDA Commissioner.

Possible outcomes from the July meeting:

• Recommend inclusion on the 503A Bulks List (favorable to compounding access)
• Recommend against inclusion (current restrictions continue)
• Recommend more evidence or further evaluation is needed

Even a favorable committee vote does not create immediate legal access. The FDA would still need to formally add the substance to the 503A Bulks List through a separate administrative process.

Whether any of these seven peptides will receive a favorable recommendation is unknown. The committee will hear presentations from stakeholders — manufacturers, researchers, patient advocates — as well as FDA staff analysis. The quality and consistency of available clinical data for many of these peptides is limited; most have never been through an IND or clinical trial process in the U.S.

The FDA Law Blog and RAPS (Regulatory Affairs Professionals Society) have both published analysis of the submissions ahead of the meeting — these are worth reading if you want deeper regulatory context.

• If one of these peptides gets listed on the 503A Bulks List, what would that mean for my ability to obtain it through a compounding pharmacy?
• Are any of these peptides being studied in clinical trials that I could access?
• What does "compounded" mean for quality and safety compared to an approved drug?

You can submit a public comment to the FDA docket before July 22, 2026. The docket number is included in the Federal Register notice published April 16, 2026. All submitted comments are public record.

The PCAC meeting on July 23–24 is open to the public and will include an open public hearing session. FDA typically livestreams advisory committee meetings; check the FDA advisory committee calendar page for access details.

After the meeting, the FDA will publish the committee's recommendations and proceed with its own review on an unspecified timeline.

The July 2026 review is a meaningful regulatory checkpoint. It is not an approval process, and a favorable vote is not guaranteed. If you're currently using any of these substances, now is a useful time to have a frank conversation with your clinician about what evidence exists for what you're taking — and what legal access might look like if the regulatory landscape changes.

federalregister.gov

fda.gov

fda.gov